COMMUNIQUÉS West-GlobeNewswire

XBiotech Announces Enrollment Completion in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Atopic Dermatitis
05/10/2018
AUSTIN, Texas, Oct. 05, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it has completed enrollment in its Phase 2, open label clinical study evaluating subcutaneous administration of [...]
Melinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program
05/10/2018
NEW HAVEN, Conn., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial [...]
Cytokinetics and Astellas Provide Updates Regarding Collaborative Skeletal Muscle Program
05/10/2018
SOUTH SAN FRANCISCO, Calif., and TOKYO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinetics”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today provided an update for their [...]
BioCorRx to Exhibit at the International Association of Chiefs of Police 2018 Annual Conference in Orlando, Florida
05/10/2018
ANAHEIM, CA, Oct. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today [...]
Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer
05/10/2018
-PyL highly sensitive, 93-99%, in reliably detecting metastatic prostate cancer lesions and highly specific, 96-99%, in confirming the absence of pelvic lymph node disease - -Study data highlights the strong positive [...]
Calithera Biosciences Highlights Breadth of Innovative Pipeline at R&D Day
05/10/2018
-Updated response rate of 50% in advanced renal carcinoma treated with CB-839 + cabozantinib -CB-839 clinical trial collaboration with Pfizer -Presentation of INCB001158 data expected in 1H2019 -R&D day hosted today [...]
Chimerix Presents Results from Multiple Ascending Dose Study of IV Brincidofovir at IDWeek
05/10/2018
DURHAM, N.C., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced data from the company’s Phase 1 study [...]
Protalix BioTherapeutics Presents Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018
05/10/2018
~Preliminary Results Indicate Significant Improvement in Kidney Function in Patients Switched from agalsidase alfa (Replagal®) to pegunigalsidase alfa (PRX-102)~ A deterioration trend in patients’ kidney function on [...]
Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE® (palbociclib) and talazoparib in Combination with CB-839
05/10/2018
Phase 1/2 trials expected to initiate 1Q2019 SOUTH SAN FRANCISCO, Calif., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on the development [...]
Amicus Therapeutics Announces Positive 18-Month Data in Pompe Disease Phase 1/2 Study at 23rd International Annual Congress of the World Muscle Society
05/10/2018
Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers Continue Out to Month 18 for both ERT-Naïve and ERT-Switch Patients Very Low Rate (<1%) of Infusion Associated [...]
T2 Biosystems Reports Granting of Inducement Awards
05/10/2018
LEXINGTON, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, [...]
Canada House Wellness Group Inc Announces Scott Purdy’s Departure
05/10/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc ("Canada House" or the "Company") (CSE: CHV) announces that [...]
K2M Group Holdings, Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders
05/10/2018
LEESBURG, Va., Oct. 05, 2018 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (Nasdaq: KTWO) (the “Company” or “K2M”), announced today that it has set a record date and meeting date for a special meeting of its stockholders [...]
RadNet Enters the Long Island, New York Market with the Acquisition of Medical Arts Radiology
05/10/2018
LOS ANGELES, Oct. 05, 2018 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services today reported it acquired [...]
RavenQuest Engages Link Media LLC to Provide Market Awareness to the USA Market
05/10/2018
VANCOUVER, British Columbia, Oct. 05, 2018 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) RavenQuest BioMed Inc. has retained Link Media LLC to [...]
Healthy Stomach Day – aroused wide interest and increased awareness on stomach health
05/10/2018
Press release 5th of October 2018 at 12.10 PM local time International Healthy Stomach Initiative (HSI) organized on Tuesday, October 2, 2018 in several countries all over the world public events aiming to increase the [...]
Terveystalo Plc: The Finnish Competition and Consumer Authority applies for an extension for investigating the transaction between Terveystalo and Attendo
05/10/2018
Terveystalo Plc Stock Exchange release 5 October 2018 at 09:00 a.m EEST Terveystalo Plc ("Terveystalo") has on 17 May 2018 signed an agreement to acquire the Finnish healthcare operations of Attendo AB (publ) ("Attendo [...]
Rule 2.9 Announcement
05/10/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 5 October 2018 [...]
VALNEVA Announces FDA Approval of Accelerated IXIARO® Vaccination Schedule
05/10/2018
Valneva Announces FDA Approval of Accelerated IXIARO ® Vaccination Schedule Saint Herblain (France), October 5, 2018 - Valneva SE ("Valneva" or "the Company"), a commercial stage biotech company focused on developing [...]

Pages